20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Pulse Biosciences Inc (PLSE) operates in the MEDICAL INSTRUMENTS & SUPPLIES industry and is headquartered in Miami, United States with about 116 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, PLSE reported $0M in revenue and ($73M) in net income.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
Interactive charts & full statements → Open the PLSE valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1M | $0M | $0M | $0M | $1M | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | ($1M) | ($1M) | ($1M) | ($11M) | ($1M) | ($1M) | ($1M) | ($1M) | ($1M) | ($1M) | $0M | $0M |
| Gross Margin % | -21.6% | -360.0% | — | 13411.1% | -1606.3% | -38.8% | -960.5% | — | — | -269.2% | -977.9% | — | — |
| Operating Income (EBIT) | ($83M) | ($77M) | ($56M) | ($44M) | ($58M) | ($63M) | ($50M) | ($48M) | ($38M) | ($26M) | ($10M) | ($4M) | $0M |
| Operating Margin % | -7007.8% | -21982.6% | — | 484155.6% | -8293.9% | -4443.9% | -43828.9% | — | — | -10451.0% | -14097.1% | — | — |
| Net Income | ($80M) | ($73M) | ($54M) | ($42M) | ($59M) | ($63M) | ($50M) | ($46M) | ($38M) | ($26M) | ($10M) | ($3M) | $0M |
| Net Margin % | -6755.8% | -20794.6% | — | 469000.0% | -8421.9% | -4454.2% | -43628.9% | — | — | -10351.0% | -13997.1% | — | — |
| EBITDA | ($80M) | ($72M) | ($52M) | ($40M) | ($57M) | ($62M) | ($49M) | ($47M) | ($37M) | ($25M) | ($9M) | ($4M) | $0M |
| Earnings Per Share (EPS) | $-1.18 | $-1.08 | $-0.92 | $-0.88 | $-1.74 | $-2.26 | $-2.14 | $-2.22 | $-2.20 | $-1.73 | $-0.86 | $-0.37 | $-0.19 |
| Shares Outstanding (M) | 69M | 67M | 58M | 48M | 34M | 28M | 23M | 21M | 17M | 15M | 11M | 8M | 3M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $1M | $2M | $0M |
| Gross Profit | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $0M |
| Gross Margin % | 37.1% | 7.7% | -96.6% | -224.4% | — | -34.0% | 50.0% | — |
| Operating Income (EBIT) | ($25M) | ($19M) | ($18M) | ($20M) | ($20M) | ($18M) | ($20M) | ($14M) |
| Operating Margin % | -5823.0% | -4775.6% | -6914.0% | -23682.6% | — | -2168.8% | -1217.6% | — |
| Net Income | ($25M) | ($19M) | ($17M) | ($19M) | ($19M) | ($17M) | ($19M) | ($13M) |
| Net Margin % | -5681.3% | -4633.7% | -6603.4% | -22540.7% | — | -2018.6% | -1165.0% | — |
| EBITDA | ($25M) | ($19M) | ($17M) | ($19M) | ($19M) | ($17M) | ($19M) | ($12M) |
| Earnings Per Share (EPS) | $-0.36 | $-0.27 | $-0.26 | $-0.29 | $-0.28 | $-0.25 | $-0.33 | $-0.21 |
| Shares Outstanding (M) | 69M | 68M | 67M | 67M | 67M | 67M | 58M | 61M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($61M) | ($54M) | ($36M) | ($33M) | ($47M) | ($54M) | ($35M) | ($34M) | ($24M) | ($11M) | ($8M) | ($3M) | $0M |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $0M | $3M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($61M) | ($54M) | ($36M) | ($33M) | ($47M) | ($55M) | ($36M) | ($35M) | ($24M) | ($14M) | ($8M) | ($3M) | $0M |
| FCF Margin % | -5180.4% | -15553.4% | — | 368466.7% | -6773.4% | -3845.8% | -31408.8% | — | — | -5521.5% | -11933.8% | — | — |
| Dividends Paid | — | — | — | — | — | $1M | — | $1M | — | $0M | $0M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($19M) | ($15M) | ($15M) | ($13M) | ($13M) | ($14M) | ($9M) | ($9M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($19M) | ($15M) | ($15M) | ($13M) | ($13M) | ($14M) | ($9M) | ($9M) |
| FCF Margin % | -4331.6% | -3647.9% | -5628.8% | -15233.7% | — | -1630.5% | -552.7% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $116M | $96M | $132M | $59M | $78M | $54M | $41M | $42M | $71M | $50M | $26M | $14M | $18M |
| Cash & Cash Equivalents | $102M | $81M | $118M | $44M | $61M | $29M | $12M | $7M | $51M | $3M | $2M | $4M | $7M |
| Total Liabilities | $16M | $15M | $18M | $15M | $80M | $19M | $18M | $11M | $4M | $4M | $1M | $1M | $2M |
| Total Debt (Short + Long-Term) | $2M | $2M | $1M | $1M | $67M | $1M | $1M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $100M | $81M | $115M | $44M | ($2M) | $36M | $23M | $31M | $66M | $46M | $25M | $14M | $16M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PLSE viewer.
About TickerBase · Data methodology & sources · Privacy · Terms